Zyvox (Linezolid)
Brand Names: Zyvox
Methodology & AI Transparency ⓘ
Zyvox (Linezolid) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Zyvox is a prescription brand-name oxazolidinone antibacterial product delivering active moiety Linezolid (cross-referenced at /meds/linezolid), registered by Pharmacia & Upjohn Company LLC under NDC 0009-5136, 0009-5138.
- 2 Real-world patient consensus: Zyvox links directly to generic Linezolid (/meds/linezolid) under FDA SPL 2025-10-22 (NDC 0009-5136).
- 3 Typical cash cost range: 30-day cash pricing ranges from $26.03 on Cost Plus Drugs to $68.98 walk-in retail (NADAC $2.1500/unit).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Zyvox (Linezolid) include nausea (11.4%), headache (10%), diarrhea (8.7%).
Ask our AI Specialists anything about Zyvox (Linezolid)
Zyvox (Linezolid) Mechanism, CYP450 Pathways & DailyMed Monograph
Zyvox is a prescription brand-name oxazolidinone antibacterial product delivering active moiety Linezolid (cross-referenced at /meds/linezolid), registered by Pharmacia & Upjohn Company LLC under NDC 0009-5136, 0009-5138. Updated in FDA DailyMed SPL on 2025-10-22, this branded presentation (100 mg/5mL Granule, for Suspension; 600 mg/1 Tablet, Film Coated) supports Linezolid Injection is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the.
Pharmacologically, Zyvox derives its clinical activity from Linezolid, a oxazolidinone antibacterial molecule with class-characteristic hepatorenal disposition. Branded finished-dosage manufacturing (100 mg/5mL Granule, for Suspension; 600 mg/1 Tablet, Film Coated; registered by Pharmacia & Upjohn Company LLC) governs excipient dissolution and release kinetics while maintaining bioequivalence benchmarks relative to reference Linezolid (CMS NADAC $2.1500/unit vs. $68.98 retail).
Clinical clearance of Zyvox (Linezolid) (Oxazolidinone Antibacterial) relies on phase i/ii hepatic conjugation of zyvox (linezolid) coupled with glomerular and tubular renal excretion with a Approximately 9–17 hours terminal plasma half-life for Zyvox (Linezolid) half-life; patients absorbing at Estimated 69%–81% oral systemic absorption for Zyvox (Linezolid) bioavailability typically observe target onset around peak plasma concentration (tmax) reached 1–2 hours post-dose for zyvox (linezolid).
FDA clinical labeling for Zyvox (Linezolid) restricts administration in prior anaphylaxis, angioedema, or severe hypersensitivity to linezolid or zyvox (linezolid) excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2025-10-22 zyvox (linezolid) spl across 100 mg/5mL Granule, for Suspension, 600 mg/1 Tablet, Film Coated, 200 mg/100mL Injection, Solution, 600 mg/300mL Injection, Solution, 600 mg/300mL Injection, with self-reported patient tracking dominated by nausea (11.4% of reports), headache (10% of reports), diarrhea (8.7% of reports).
Combining Zyvox (Linezolid) with MAOIs within a 14-day washout window risks severe serotonergic or pressor toxicity.
Avoid overlapping oxazolidinone antibacterial prescriptions alongside Zyvox (Linezolid) to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Linezolid or Zyvox (Linezolid) excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2025-10-22 Zyvox (Linezolid) SPL
Logged Side-Effect Incidence (12 Reports)
Zyvox (Linezolid) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Zyvox (Linezolid))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Ceftobiprole was non-inferior to ceftriaxone ± linezolid for clinical success at Day 3 according to the current 2020 FDA CABP Guidance. PloS one • 2025-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40554538 ↗ |
| Can This Approach Help? Inside the Latest Research on A Phase III multicentre, randomized, gold-standard blind trial to evaluate the Contezolid 800 mg q12h is as effective as linezolid for treatment of cSSTIs in adults, but safer than linezolid in terms of haematological abnormalities. The Journal of antimicrobial chemotherapy • 2022-05-29 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35265985 ↗ |
| Can This Approach Help? Inside the Latest Research on How the body absorbs the medicine, bactericidal activity and toxicity of short These data indicate that the studied doses of linezolid and moxifloxacin could be the right balance between effectiveness and safety, strengthening the WHO recommendation that BPaLM is the preferred regimen for... Nature communications • 2026-06-10 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42270675 ↗ |
Zyvox (Linezolid) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.1500/unit (~$64.50/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $26.03 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $68.98 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $29.93 / mo | View logs ↓ |
Zyvox (Linezolid) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Zyvox (Linezolid) RxNorm Concept ID | 311347-B00095136 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.1500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $68.98 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $26.03 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 77.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Zyvox (Linezolid) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Zyvox (Linezolid): FDA labeling (2025-10-22, NDC 0009-5136), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Zyvox (Linezolid) community threads and patient logs by age, biological sex, dosage, and treatment duration.